Comparison of metoclopramide and ondansetron on nausea and vomiting in renal colic

Comparison of metoclopramide and ondansetron in the treatment of nausea and vomiting in patients with Renal colic

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016091023552N9

Enrollment

180

Registered

2016-10-01

Start date

2015-09-13

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Renal colic. Condition 2: Nausea and vomiting. Unspecified renal colic Nausea and vomiting

Interventions

Intervention 1: Control: These patients receive 10 milligram metoclopramide(made in Osvah Pharmaceutical Company in Islamic Republic Of Iran) single dose, intravenously. Intervention 2: Intervention:

Treatment - Drugs

Control: These patients receive 10 milligram metoclopramide(made in Osvah Pharmaceutical Company in Islamic Republic Of Iran) single dose, intravenously.

Intervention: These patients receive 4 milligram ondansetron(made in Shahredaru Pharmaceutical Company in Islamic Republic Of Iran) single dose, intravenously.

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Renal colic patients with nausea and vomiting; ASA I or II; age between 18 to 80 years old; Patients satisfaction on participation in the study. Exclusion criteria: Systolic blood pressure lower than 90 mmHg; Unstable hemodynamic; Opium addiction; history of uncontrolled diseases (Parkinson, Restlessness syndrome, Epilepsy, GI bleeding, Pheochromocytoma); Recent use of CNS depressant drugs; Recent use of antiemetic drugs; allergy to the drugs used in this study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nausea severity. Timepoint: 0 and 30 minutes after injection. Method of measurement: visual analogue scale.;Number of vomiting. Timepoint: from 30 minutes before until 30 minute after injection. Method of measurement: questionnaire.	—

Secondary

Measure	Time frame
Blood pressure. Timepoint: 0 and 30 minutes after injection. Method of measurement: sphygmomanometer.;Pulse rate. Timepoint: 0 and 30 minutes after injection. Method of measurement: pulse rate in 1 minute.;Respiratory rate. Timepoint: 0 and 30 minutes after injection. Method of measurement: Respiratory rate in 1 minute.;Body Tempreture. Timepoint: 0 and 30 minutes after injection. Method of measurement: Thermometer.;Need to excessive drugs. Timepoint: 30 minutes after injection. Method of measurement: Observation.	—

Measure

Time frame

Blood pressure. Timepoint: 0 and 30 minutes after injection. Method of measurement: sphygmomanometer.;Pulse rate. Timepoint: 0 and 30 minutes after injection. Method of measurement: pulse rate in 1 minute.;Respiratory rate. Timepoint: 0 and 30 minutes after injection. Method of measurement: Respiratory rate in 1 minute.;Body Tempreture. Timepoint: 0 and 30 minutes after injection. Method of measurement: Thermometer.;Need to excessive drugs. Timepoint: 30 minutes after injection. Method of measurement: Observation.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Abolfazl Jokar

Vali-e-Asr hospital

dr.a.jokar@gmail.com+98 86 3223 1104

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026